Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy
04:05pm, Tuesday, 15'th Oct 2024
REDWOOD CITY, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral coval
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
09:30am, Sunday, 13'th Oct 2024
The future of the weight loss market might not revolve around GLP-1 drugs.
WeightWatchers stock price skyrockets on news that it will offer a compounded GLP-1 weight-loss drug like Wegovy
04:12pm, Wednesday, 09'th Oct 2024
WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs, a move that sent its shares s
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
09:05am, Wednesday, 09'th Oct 2024
DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / October 9, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company
WeightWatchers' stock soars after adding compounded GLP-1 treatment to its offering
10:38am, Tuesday, 08'th Oct 2024
“With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management solution that is both accessible and affordable,” said Interim Chief Exe
GLP Capital Partners and Ares Management Corp to Merge in $5.2 Billion Deal
10:31am, Tuesday, 08'th Oct 2024
GLP Group has announced the merger of its fund management business, GLP Capital Partners (GCP), with Ares Management Corporation, a leading alternative asset management company listed on the New York
Lexaria Updates Current GLP-1 Market
09:20am, Tuesday, 08'th Oct 2024
KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on
Concerns Over Muscle Loss with GLP-1 Weight Loss Drugs (LLY, NVO, REGN)
02:10am, Monday, 07'th Oct 2024
Clinical studies highlight that Eli Lilly (LLY, Financial) and Novo Nordisk's (NVO) weight loss drugs result in significant lean body mass reduction, with 25% and 40% of weight loss attributed to musc
Midstream Energy - Relative Quality
07:37am, Friday, 04'th Oct 2024
Many midstream energy companies pay stable, well-supported distributions or dividends with yields well over 5%. The relative quality of twenty-nine midstream energy companies was evaluated by means of
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
08:30am, Thursday, 03'rd Oct 2024
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and well
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, t
Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
11:37am, Wednesday, 25'th Sep 2024
Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to Nov
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) an
